Physician profile
James Hill
NPI 1639306053
$4,490.86
in general payments reported to CMS, 2019-2025
26 companies · $414 in 2025
The $414 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,216 · 2020: $284 · 2021: $502 · 2022: $1,091 · 2023: $492 · 2024: $491 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180 · Entertainment: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.10 |
| Entertainment | $217.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $633.24 | 2019-2025 | Hydrus Microstent |
| Johnson & Johnson Vision Care, INC. | $529.70 | 2020-2023 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $464.75 | 2019-2021 | |
| Optos, INC. | $377.60 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Abbvie INC. | $326.53 | 2022-2025 | |
| Allergan, INC. | $319.33 | 2019-2022 | |
| Horizon Therapeutics Plc | $239.61 | 2022-2023 | Tepezza |
| Amgen INC. | $168.11 | 2025 | Tepezza |
| Recordati_rare_diseases_inc. | $123.98 | 2025 | Cystadrops |
| Shire North American Group INC | $123.90 | 2019 | |
| Biotissue Holdings INC. | $121.54 | 2022 | |
| Omeros Corporation | $120.22 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $114.15 | 2024 | Eylea Hd |
| Lumenis Be INC | $111.38 | 2021 | |
| Glaukos Corporation | $107.17 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $98.25 | 2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $93.74 | 2021 | |
| Alcon Research LLC | $80.74 | 2019 | |
| Bausch & Lomb Americas INC. | $74.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $67.41 | 2021-2022 | |
| Oyster Point Pharma, INC. | $66.80 | 2022 | |
| Coopervision INC. | $46.30 | 2023 | Myday Contact Lens |
| Maculogix, INC. | $27.04 | 2019 | |
| Abb Con-Cise Optical Group LLC | $22.95 | 2019 | |
| Sight Sciences, INC. | $18.76 | 2022 | |
| Sun Pharmaceutical Industries INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.